AcuCort expected to gain patent protection in the US
AcuCort AB (AktieTorget: ACUC) today announces that the US Patent and Trademark Office (USPTO) has issued a ”Notice of Allowance” for the company’s patent application for medical formulations containing glucocorticoids for self-treatment in acute situations, ”Acute Glucocorticoid Therapy”.
”Notice of Allowance” is a part of the approval process where UPSTO confirms that the application process is completed and the issuance of the patent is now starting. The patent is expected to be issued during the second quarter 2018.
The US patent application no. 11/587,512 describes medical self-treatment with glucocorticoids in emergency situations without access to medical personnel. The invention describes and covers glucocorticoids in general, which means that the protection against competition will be wider than the specific composition of the company’s product, the fast-dissolving film Dexa ODF. The invention has previously resulted in granted patents for AcuCort in 30 countries.
“More than a billion people suffer from allergies. Dexa ODF can offer important treatment for many allergics in emergency situations. Patent protection in key markets is an essential component in the commercialization of Dexa ODF. The news from the US Patent and Trademark Office is thus strategically important,” says Mats Lindfors, CEO of AcuCort.
About glucocorticoids
Every year millions of patients the world over use medicines containing glucocorticoids, for example against allergy and viral croup. Also cancer patients suffering from nausea and vomiting in connection with chemotherapy (CINV) use this type of drug. One big disadvantage is that these drugs are not perceived to be user-friendly or require medical staff. First having to dissolve the tablets in water can be very awkward in an acute situation, for the sufferers as well as for other persons helping them. The sufferer may have difficulties swallowing, and thus a fast-dissolving film to be place on the tongue, with the same effect as the tablet, may have a wide application area.
This information is information that AcuCort AB is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure through the agency of the contact person above, on February 15, 2018.
For more information
Mats Lindfors, CEO, AcuCort AB
Telefon: +46 70 790 58 15
E-post: mats.lindfors@acucort.se
About AcuCort
AcuCort develops and commercializes Dexa ODF, a fast-dissolving oral film containing the glucocorticoid dexamethasone. Dexa ODF is a smart product in a new, innovative, patented and user-friendly dosage form primarily for the treatment of acute allergic reactions, viral croup in children and chemotherapy-induced nausea and vomiting (CINV). Dexa ODF is estimated to have a short time to market as the company only has to repeat a previously successful bioequivalence study before applying for market approval in Europe. Please visit www.acucort.se
Tags:
